Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Quick Stats
Jan 30, 202656.3
AI Score
HOLD1.26
Volume Ratio
Feb 04, 2026
Next Earnings
12
+ve Days (30d)
18
-ve Days (30d)
VKTX Stock Summary
Last updated Jan 30, 2026
VKTX is currently trading at $29.04, positioned below its 200-day moving average of $31.12, suggesting bearish momentum. The stock has a 52-week range of $18.92 to $43.15.
Technical Analysis: The 50-day moving average stands at $34.54, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 34.513, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.289, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates VKTX at 56.3/100 with a HOLD recommendation.
VKTX (Viking Therapeutics, Inc) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 34.513 |
| CMF (20) | -0.289 |
| ROC (10) | -8.908 |
| ADX (14) | 12.766 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -1.22 |
| AROONOSC (14) | -78.571 |
| WILLAMS %R (14) | -98.723 |
| MFI (14) | 36.699 |
VKTX Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
VKTX Price vs Max Options Open Interest
VKTX Max Change In Options Open Interest
VKTX Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VKTX Daily Out of Money Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VKTX Daily In the Money Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VKTX Most Active Options by Volume(near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Viking Therapeutics, Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
VKTX Moving Averages Analysis
VKTX (Viking Therapeutics, Inc) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 32.02 |
| 20 | 32.24 |
| 30 | 33.37 |
| 50 | 34.54 |
| 100 | 33.17 |
| 200 | 31.12 |
VKTX Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 3.3 billion |
| Earnings/Share ($) | -2.12 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -2.6133 |
| EPS Estimate Next Year ($) | -3.7183 |
| WallStreet Target Price ($) | 93.3889 |
| Most Recent Quarter |
Viking Therapeutics ($VKTX) stock is expected to rise as reality sets in, with a drug in phase 3 showing better efficacy and tolerability than Tirzapetide. The drug is predicted to have the highest peak sales in the world. Keytruda had the highest sales of $30 billion, but Tirzepatide is expected to reach close to $40 billion this year. With a market cap of $3 billion, VKTX is poised to challenge Lilly's drug, which has a market cap of over $300 billion. The stock is predicted to reach four digits, making it a potential millionaire maker for patient investors.
Updated 2025-10-06 01:00:02